Stock Track | JIUYUAN GENE Plummets 5.08% Intraday on Weak FY25 Results with Revenue Decline

Stock Track
Mar 31

JIUYUAN GENE's stock plummeted 5.08% during intraday trading on Tuesday, following the release of its full-year 2025 financial results which showed a decline in revenue.

The company reported that revenue for FY25 slipped 4.6% to RMB 1.3 billion. The decline was driven mainly by lower orthopedic product sales, attributed to ongoing DRGs/DIP healthcare payment reforms and online listing-related price cuts which pressured the business.

While the company's gross margin widened by 1.7 percentage points to 80.7% due to lower raw material costs and lean production management, and profit attributable to owners remained largely unchanged at RMB 138 million, the top-line contraction appears to have concerned investors, leading to the significant sell-off during the trading session.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10